Bachem 的持平业绩说明了肽 CDMO 的情况

为什么股价表现不足以代表供应合作伙伴的价值

收入增长通常是由与您的计划无关的组合带来的. 开发阶段的工作随着管道流量的增加而扩展，并消耗小容量的容量, 灵活的增量; 商业 API 供应取决于长期稳定运行的合格生产线. 当您需要的细分市场正在收缩时，供应商可以发布强劲的增长数字 - 甚至更高, 原来是.

资本支出是一个承诺, 不是一种能力. 已公布的产能需要调试, 资质, 并在发布材料之前配备人员. 全球多肽CDMO产能投资创五年新高 2026, 大致跨越美元 2.4 到年中将达到 10 亿, 但约束因素是人才——工艺化学, 冻干工程, QA/QC——而不是钢铁.

使用率数据为汇总数据, 不是个人的. 美国肽 CDMO 产能约为 78-85% 2026, 商业规模的 GLP-1 工作更加严格——超出了需求驱动的延迟开始达到临床时间表的程度, 大致低于 90% 下游瓶颈增加质量风险的阈值. 该带的两端都不会告诉您是否 你的 插槽存在.

所有这些都不会使大型供应商成为糟糕的选择. 适用于资本密集型商业 API 项目, 广泛的监管范围和多地点供应, 规模往往是决定性的. 点比较窄: 大小是关于你的程序的假设, 不是结论. 下面的四个支柱是您测试它的方法.

四大价值支柱的评分矩阵

下面的框架是为肽供应商评估而构建的——它将供应商价值视为四个可独立验证的维度. 财务规模不作为衡量标准出现, 因为再多的东西也无法替代它们中的任何一个.

权重随程序阶段而变化: 发现筛选应权衡技术深度和周转率, 而支持 IND 的商业计划应更加重视质量一致性和产能透明度. 不应该改变的是对所有四个方面的证据的要求.

质量一致性和批次间一致性——可验证, 不抱负

质量一致性意味着同一肽的连续生产批次在预定义的同一性限度内匹配, 纯度, 杂质概况, 以及与性能相关的属性. 这不是意图声明. 这是一个有记录的, 控制系统的可审计属性.

携带证据的文件

分析证书的有用性取决于其特异性: CoA 是否与您收到的确切批次相关, and is the underlying data readable rather than summarized? Reverse-phase HPLC is the standard purity readout, typically detected at 214–220 nm, but the chromatogram, 柱子, and gradient should be visible — not just a percentage. Orthogonal identity confirmation comes from ESI-MS or MALDI-MS tied to the same lot. Depending on use case, the release panel may extend to water and counterion content, residual solvents under ICH Q3C(R9), endotoxin by USP ⟨85⟩ testing, 不育, and amino acid analysis.

Specifications should be defined in the attribute categories regulators expect — identity, 纯度, 杂质, content or strength, plus relevant physicochemical characteristics — following ICH Q6B specification principles. In the EU, the EMA’s 合成肽开发和生产指南, adopted December 2025 and effective 1 六月 2026, sets peptide-specific expectations for process, characterisation, 规格, and analytical control. A partner who maps your program onto that structure is demonstrating control; one who cannot is describing intentions.

批次间的实际含义是什么

Consistency is a band, not a number. A purity series reading 95%, 92%, 98%, 88% across successive lots without explanation is not manufacturing noise — it is a control-system signal. The useful question is not “what is your typical purity?” but “show me five consecutive lots of a comparable peptide, side by side.”

Two habits separate rigorous buyers from hopeful ones. Keep every batch-specific certificate and treat it as a data point, not a disposable PDF. Then compare each new lot against your own historical lots — purity, secondary-peak fingerprint, retention-time behaviour — rather than the certificate’s headline figure. For filing-bound programs, an IND-enabling package typically presents batch analysis across at least three consecutive lots, with area-percent purity consistency within roughly ±1.0% and matching impurity fingerprints.

验证清单

Peptide Manufacturing Capacity Transparency — Five Different Numbers Called “Capacity”

Capacity transparency means a supplier separates what is announced from what is installed, what is qualified from what is available to you, and can commit the difference in writing. For most buyers this is the most consequential gap between a deck and a contract.

铭牌, 已安装, 合格的, 坚定的

多肽合成 Capacity is not one figure. Ask for it in tiers.

A supplier that answers only at the nameplate level is not necessarily evasive — most organizations do not publish tier-separated figures. Ask anyway — the quality of the answer is itself the signal.

下游瓶颈决定了真正的天花板

Synthesis capacity is rarely the true constraint. For many complex or high-volume peptides, deliverable volume is governed by preparative reverse-phase HPLC — column inventory, pass count, diameter — plus lyophilization 合成肽 throughput, 溶剂回收, cold storage, and analytical suite availability. Prep-HPLC suite count and column diameter are a more direct proxy for usable clinical-grade output than reactor volume.

⚠️警告: Because utilization in the mid-80% range leaves little slack, reserving a slot against announced 而不是 合格的 capacity is one of the most common — and most expensive — procurement errors in peptide programs.

将能力转化为合同承诺

Capacity becomes reliable only when it is written into governing documents. Lead-time reality first: capacity reservation at leading peptide CDMOs now runs in the 18–24 month range for commercial-scale work, well beyond the 6–12 month norms of 2019–2021.

The quality agreement defines responsibilities otherwise left to project-level improvisation: batch records, 发布测试, records retention, 审计权, 变更控制, deviation closure, and regulatory support. The service-level schedule quantifies performance — on-time-in-full delivery, right-first-time execution, deviation closure times, release timing, escalation response — and states what happens when a threshold is missed. A common commercial benchmark for on-time, in-full delivery is 95% 或更高, with remediation defined in the contract rather than negotiated after a failure. Business continuity language covers redundancy, backup suppliers, and constraints at the specific site named in your proposal.

If your program carries real risk, a qualified secondary route is not a sign of distrust — it is the standard structure of resilient peptide supply, and it belongs before the first campaign, not after the first delay. Partners who support peptide process development from route selection through scale-up can discuss continuity alongside capacity. 多肽生产

验证清单

Technical Depth — Where “We Can Do It” Becomes Evidence

Technical depth means demonstrated ability to solve sequence-specific problems, not a catalogue of reaction types. The distinction matters because the peptides that fail are rarely the easy ones.

序列级测试用例

Depth is testable against specific difficulty classes: 长链; aggregation-prone or hydrophobic segments that resist coupling and purification; multiple disulfide bridges needing controlled oxidative folding; cyclization and stapling chemistry; non-natural and D-amino acid residues; and conjugates of peptide to protein, payload, or polymer. Separating closely eluting isomers and deletion by-products is its own competence — frequently the one that decides whether a program meets its timeline.

Scale is necessary for capital-intensive commercial API work — a dedicated large-scale SPPS suite with purification and analytical infrastructure is a substantial capital commitment. It is not evidence that your sequence can be made. Route selection, resin and loading strategy, impurity risk assessment, and purification planning are sequence-specific judgements, and hard programs are won or lost on them.

监管素养作为化学深度的读出

Ask how a program maps onto applicable guidance. The EMA synthetic-peptide guideline covers process, characterisation, 规格, and analytical control in peptide-specific terms. ICH Q6B specification principles define the attribute categories behind a defensible release strategy, 和 我Q3C(R9) on residual solvents sets limits that peptide manufacturing routinely approaches given solvent volumes. A supplier who discusses these fluently is describing control; one who deflects to marketing language is disclosing its absence.

Whether the chemistry runs on solid-phase synthesis, 微生物发酵, or a hybrid route should follow from the sequence rather than a preferred platform. 一个 custom peptide synthesis partner who works across both — and across modification classes spanning 300+ functional-group options — can choose the route the molecule needs. A supplier locked into one platform will route your peptide through it regardless.

CTA: Have a sequence that failed elsewhere? Send the sequence and the specific failure mode — a technical review of the route and purification strategy is more useful than a capability brochure.

验证清单

客户成果 - 您可以验证的文档

The final pillar replaces claims with records. It is the cheapest to check and the one most often skipped because asking for it can feel adversarial. Treat it as due diligence instead: you are verifying records, not challenging intentions.

审核历史记录胜过证书计数

Ask for review history rather than certification counts: named programs where the supplier’s impurity-control strategy was reviewed and accepted, in which markets, what deficiency questions were raised, and how they were answered. Certificate counts describe paperwork; deficiency-and-response history describes capability under scrutiny. A complementary signal is publication footprint — peer-reviewed work in the last three years demonstrating synthesis of peptides with comparable length, 疏水性, or modification complexity.

揭示真实风险的参考问题

Reference calls tend to produce reassurance because they ask reassuring questions. Four better ones:

1. How accurate were the original transfer and first-batch timelines once real data and documentation handoff began?

2. Did the supplier surface site-level capacity or material constraints early enough to protect the development plan?

3. How were deviations, CAPAs, and change controls handled when the program was under operational stress?

4. Which costs or responsibilities only became visible after contracting — analytical work, 验证, storage?

The fourth question is the one most likely to change a decision: 分析发展, 验证, and storage are where budget expectations most often move after contracting. A supplier who pre-empts those items has run programs before, and is not learning on yours.

Analytical posture matters too. Organizations that run peptide testing and analytics alongside manufacturing are inviting scrutiny of their own release data — the posture you want from a partner whose certificate you are about to rely on.

验证清单

必备品, 危险信号, 和您的自我评估记分卡

Must-haves — walk away if unmet: lot-specific, unredacted certificates with orthogonal analytical data for the lots you will use; a quality agreement covering batch records, 变更控制, deviation closure, and audit rights; the specific site and line that will produce your material; a named technical contact with authority over the route; 和, for clinical-stage work, batch data across consecutive lots with stable impurity fingerprints.

Red flags — investigate before proceeding: inability to name the exact site, line, or recent comparable programs; vague proposals around failed batches, capacity holds, or extra validation work; “end-to-end” claims that hide third-party steps; reference customers describing late surprises on deviations, scheduling, or documentation; purity figures that move across lots without explanation.

Tolerable gaps — price accordingly: longer lead times at a smaller specialist, often offset by faster technical response; a narrower regulatory footprint, acceptable for discovery and many preclinical programs; less automation, frequently offset by direct access to the scientists running your campaign.

Now score. Rate shortlisted partners from 1 到 5 on each row, weighting the rows to your program stage before you total them. The weights, not the raw scores, are what most buyers get wrong.

One interpretation rule matters more than the totals: a score of 4 或者 5 on technical depth with a 2 on quality consistency is the most dangerous profile in the table. It describes a vendor capable of an impressive first campaign and unable to reproduce it. Weight accordingly.

首先做什么

要点: A rolling forecast, a documented dual-source decision, and a documentation audit — in that order — resolve more supplier risk than any negotiation tactic applied later.

Start with a rolling forecast. Map peptide demand across the next 18–24 months — batch sizes and quality categories included — and give shortlisted suppliers that picture before requesting quotes. Forecast clarity is the most effective way to get a real answer on slot availability, because it lets a supplier respond to a concrete plan rather than a hypothetical.

Then make the dual-sourcing decision deliberately, before capacity pressure forces it. Decide which programs can tolerate a single source, then qualify a secondary route for those that cannot. Qualifying a supplier against a deadline costs materially more than qualifying one on your own schedule.

最后, audit documentation before anything else: lot-specific certificates, trend data on comparable peptides, and the quality agreement and SLA templates that will govern the relationship. Most supplier risk is visible in documents, and documents can be reviewed without a site visit or a purchase order.

When you are ready to move from evaluation to execution, partners who can speak to route, 规模, and release strategy in the same conversation make the transition shorter. MOL Changes runs that conversation across 定制肽合成, 分析验证, 无菌生产, and scale-up — or bring a specific sequence and its constraints to a technical discussion. That is a faster route to a decision than another round of capability slides.